Table 1.
Ongoing androgen deprivation and targeted therapies and clinical trials in prostate cancer– ordered by drug name.
| Identifier | Treatment/Intervention | Phase | Trial Outcome |
|---|---|---|---|
| NCT00473512 | Abiraterone acetate, Dexamethasone | 1&2 | C |
| NCT02125357 | Abiraterone acetate, Enzalutamide | 2 | C |
| NCT01309672 | Abiraterone acetate, Prednisone | 2 | PC, O |
| NCT02217566 | Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT) | 2 | C |
| NCT01715285 | Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT), Prednisone | 3 | C |
| NCT03012321 | Abiraterone/prednisone, olaparib or Abiraterone/prednisone + Olaparib | 2 | O |
| NCT01085422 | ABT-888 (oral PARP inhibitor), temozolomide | 1 | C |
| NCT03511196 | Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone | 1 | O |
| NCT02489318 | Apalutamide, Androgen Deprivation Therapy (ADT) | 3 | PC, O |
| NCT03767244 | Apalutamide, Androgen Deprivation Therapy (ADT) | 3 | O |
| NCT01946204 | Apalutamide, current treatment | 3 | PC, O |
| NCT03888612 | ARV-110 | 1&2 | O |
| NCT00541047 | Bicalutamide, goserelin acetate, leuprolide acetate, radiation therapy | 3 | O |
| NCT02485691 | Cabazitaxel, enzalutamide, abiraterone acetate, prednisone | 4 | C |
| NCT02893917 | Cediranib + Olaparib vs Olaparib | 2 | O |
| NCT00268476 | Celecoxib, Docetaxel, Prednisolone, ADT, Zoledronic Acid, Abiraterone,: Radiotherapy to the prostate, Enzalutamide, Metformin, Transdermal Oestradiol | 2&3 | O |
| NCT02200614 | Darolutamide | 3 | C |
| NCT02972060 | Darolutamide (ODM-201), ADT | 2 | O |
| NCT02799602 | Darolutamide (ODM-201), Standard ADT, Docetaxel | 3 | O |
| NCT04136353 | Darolutamide, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy | 3 | O |
| NCT01212991 | Enzalutamide | 3 | C |
| NCT02677896 | Enzalutamide | 3 | PC, O |
| NCT01664923 | Enzalutamide, Bicalutamide | 2 | C |
| NCT02446444 | Enzalutamide, Conventional NSAA, LHRHA, External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost) | 3 | O |
| NCT02446405 | Enzalutamide, NSAA, LHRHA or Surgical Castration | 3 | C |
| NCT03141671 | GnRH, Bicalutamide, Salvage radiation, Abiraterone, Prednisone, Apalutamide | 2 | O |
| NCT03860987 | Goserelin, Enzalutamide, Abiraterone, Prednisone, Radical Prostatectomy | 2 | O |
| NCT00726596 | Hydroxychloroquine | 2 | C |
| NCT02854436 | Niraparib | 2 | O |
| NCT04592237 | Niraparib, cabazitaxel, carboplatin,cetrelimab, | 2 | O |
| NCT04194554 | Niraparib, leuprolide, abiraterone acetate, Stereotactic body radiotherapy (SBRT) | 1&2 | O |
| NCT04030559 | Niraparib, niraparib tosylate monohydrate | 2 | O |
| NCT04951492 | Olaparib | 2 | O |
| NCT01682772 | Olaparib | 2 | C |
| NCT03047135 | Olaparib following radical prostatectomy | 2 | O |
| NCT01972217 | Olaparib, abiraterone | 2 | PC, O |
| NCT05167175 | Olaparib, abiraterone acetate, prednisone | 2 | O |
| NCT03787680 | Olaparib, AZD6738 (ATR inhibitor) | 2 | O |
| NCT02324998 | Olaparib, degarelix | 1 | C |
| NCT04336943 | Olaparib, durvalumab | 2 | O |
| NCT03810105 | Olaparib, durvalumab | 2 | O |
| NCT02987543 | Olaparib, enzalutamide, abiraterone acetate | 3 | PC, O |
| NCT03317392 | Olaparib, radium Ra 223 dichloride | 1&2 | O |
| NCT03516812 | Olaparib, testosterone enanthane, testosterone cypionate | 2 | O |
| NCT05327621 | Pamiparib | 2 | O |
| NCT02362594 | Pembrolizumab | 3 | PC, O |
| NCT03834519 | Pembrolizumab (MK-3475) and olaparib vs abiraterone or enzalutamide | 3 | O |
| NCT02578680 | Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Dexamethasone | 3 | PC, O |
| NCT02787005 | Pembrolizumab, Enzalutamide | 2 | C |
| NCT02256436 | Pembrolizumab, paclitaxel, vinflunine, docetaxel | 3 | C |
| NCT03007732 | Pembrolizumab, SD-101, Leuprolide acetate, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy | 2 | O |
| NCT03777982 | Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist | 3 | O |
| NCT03809000 | Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog | 2 | O |
| NCT02952534 | Rucaparib | 2 | C |
| NCT03533946 | Rucaparib | 2 | O |
| NCT02975934 | Rucaparib vs abiraterone acetate or enzalutamide or docetaxel | 3 | O |
| NCT04455750 | Rucaparib, enzalutamide | 3 | O |
| NCT04179396 | Rucaparib, enzalutamide, abiraterone | 1 | O |
| NCT02680587 | SBRT | 2 | O |
| NCT04115007 | Stereotactic Body Radiotherapy (SBRT), Standard of care | 3 | O |
| NCT04550494 | Talazoparib | 2 | O |
| NCT04703920 | Talazoparib, belinostat | 1 | O |
| NCT04734730 | Talazoparib, bicalutamide, degarelix, goserelinacetate, leuprolide acetate, prednisone | 2 | O |
| NCT04821622 | Talazoparib, enzalutamide | 3 | O |
| NCT04824937 | Telaglenastat, talazoparib | 2 | O |
| NCT01576172 | Veliparib, abiraterone acetate, prednisone | 2 | C |
PC, primary completion; C, completed; O, on-going.